Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Intelligent Bio Solutions ( (INBS) ) just unveiled an announcement.
On February 25, 2026, Intelligent Bio Solutions announced it had successfully received and deployed the first shipment of its Intelligent Fingerprinting Drug Screening Readers manufactured under a new strategic partnership with Syrma Johari MedTech. The readers are being rolled out across construction, transportation and logistics, and manufacturing customers in the U.K. and Europe, expanding the installed base ahead of an anticipated broader U.S. market entry later in 2026.
The Syrma Johari collaboration validates fourfold increased manufacturing capacity and compliance with key quality and regulatory standards, positioning the company to speed order fulfillment while targeting annual production cost savings of more than 40% and about 20 percentage points of gross margin improvement. In parallel, the company has doubled in-house lateral flow test strip production, deepening vertical integration, boosting R&D throughput, and enabling expansion of drug testing panels tailored to different customer and regulatory needs.
Management described these manufacturing advances as a transformational step toward building a cost-efficient, scalable platform that supports margin expansion and innovation. Additional production shipments are expected throughout 2026 as Intelligent Bio Solutions builds inventory and broadens its commercial footprint in preparation for U.S. regulatory and go-to-market execution.
The most recent analyst rating on (INBS) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Intelligent Bio Solutions stock, see the INBS Stock Forecast page.
Spark’s Take on INBS Stock
According to Spark, TipRanks’ AI Analyst, INBS is a Neutral.
The score is primarily held down by very large losses and persistent negative free cash flow, alongside a clear bearish price trend. Corporate developments (financing, regained listing compliance, and initiatives aimed at margin improvement and U.S. regulatory progress) provide some upside, but do not yet outweigh the current financial and technical weakness.
To see Spark’s full report on INBS stock, click here.
More about Intelligent Bio Solutions
Intelligent Bio Solutions Inc. is a medical technology company specializing in intelligent, rapid, non-invasive testing solutions, notably its Intelligent Fingerprinting Drug Screening System that analyzes fingerprint sweat. The hygienic, cost-effective system targets recent drug use in safety-critical workplaces, serving sectors such as construction, manufacturing, transport and logistics, mining, drug treatment organizations, and coroners outside the U.S.
Average Trading Volume: 2,448,902
Technical Sentiment Signal: Sell
Current Market Cap: $6.64M
Find detailed analytics on INBS stock on TipRanks’ Stock Analysis page.